ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Acerta Pharma BV
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center